CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

NBL-015 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that Shanghai Novarock Biopharmaceutical Co., Ltd.*(上海新石生物醫藥有限公司), a subsidiary of the Company, has obtained approval granted by the National Medical Products Administration of the People's Republic of China to conduct clinical trial for NBL-015 in China. NBL-015 is a fully human anti-Claudin 18.2 monoclonal antibody discovered and developed by NovaRock Biotherapeutics Limited, a subsidiary of the Company, for treating advanced solid tumors with positive Claudin 18.2 expression, including pancreatic cancer and gastric cancer (including cancer of the gastroesophageal junction). The Phase I clinical trials will evaluate the safety, tolerability and pharmacokinetics of NBL-015 in patients with advanced solid tumors.

Claudin 18.2 is a highly specific cell-surface molecule widely expressed in gastric and pancreatic tumors. In normal tissues, Claudin 18.2 expression is strictly confined to differentiated epithelial cells of the gastric mucosa but absent from the gastric stem cell zone, thus the development of therapeutic antibodies targeting Claudin 18.2 has high anti-cancer potential. NBL-015 is optimized through protein engineering to achieve enhanced ADCC, CDC and ADCP effects. Preclinical studies of in vitro tumor cell killing and tumor mouse model have demonstrated that NBL-015 has significant advantages over similar drugs in terms of low immunogenicity, good safety, high affinity and high anti-tumor activity, providing a promising prospect of becoming the best-in-class target therapy to treat pancreatic and gastric cancer.

NBL-015 has been previously granted orphan-drug designation for the treatment of pancreatic cancer and gastric cancer by the U.S. Food and Drug Administration (FDA), and its Investigational New Drug Application (IND) has also been approved by the U.S. FDA in May 2021. In August 2021, the Group entered into a strategic collaboration agreement with Flame Biosciences Inc. ("**Flame Biosciences**"), an U.S. innovative pharmaceutical company, pursuant to which the ex-Greater China development and commercialization rights of NBL-015 was granted to Flame Biosciences.

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 2 September 2021

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.